Center for Clinical and Translational Research

Programs and Resources for Researchers

CCTR’s programs, facilities and services help ensure researchers within the center – and throughout Seattle Children’s – have the means and the opportunity to conduct safe, efficient, and ethical research involving children.

Featured Research

  • New Procedure for Treacher Collins

    A surgical paradigm shift makes it possible for kids with severely restricted airways to breathe on their own.

  • Lighting the Way for Children With Brain Tumors

    Dr. Sarah Leary serves as the lead investigator of a clinical trial evaluating tozuleristide (BLZ-100, also referred to as Tumor Paint), a tumor-targeting fluorescent imaging agent that aims to improve surgical outcomes in children with brain tumors.



In the News

  • Specific carbohydrate diet helps children with Crohn's disease and ulcerative colitis 
    2.19.2019 –

    Research from Seattle Children's has discovered that the specific carbohydrate diet (SCD) can put patients into remission without the use of drugs.
  • An Ode to Science
    10.11.2018 – Harvard News
    Congratulations to Dr. Bonnie Ramsey who was honored at the Warren Alpert Symposium for her transformative discoveries that changed the course of cystic fibrosis.
  • Seattle Children’s launches into solid tumor treatments with new CAR T immunotherapy trial
    8.7.2018 – GeekWire

    Seattle Children’s Research Institute is launching a CAR T immunotherapy clinical trial that will examine a new kind of cancer-fighting treatment. CAR T therapies have found early success in blood cancers, including leukemia and lymphoma, but have run into obstacles when it comes to solid tumor cancers like lung and breast cancer. This new trial, called STRIvE-01, is hoping to overcome those obstacles for children with sarcoma, kidney and neuroblastoma tumors. The trial will treat children whose cancer has relapsed, a group that often has few remaining treatment options. Dr. Katie Albert, the lead investigator of the trial, said the goal of this early trial is to test the safety of the new therapy and establish the best dose, although researchers also hope to see the trial make headway against patients’ tumors. “Further, we hope to observe efficacy against one or more types of tumors and minimal toxicity to normal tissues. In the best case scenario, this will simply be the first step in developing a curative therapy for our highest risk patients,” Albert said. Scientists at the Ben Towne Center for Childhood Cancer Research will reprogram the T-cells of patients in the trial to create CAR T cells designed to hunt down cancer cells that display the EGFR protein. The new trial is yet another notch in the belt of Seattle Children’s growing immunotherapy research program.
  • Build resilience in kids to prevent suicide
    5.29.2018 – 

    Suicide is the number one cause of death for children in Washington state between 10-14 years old. Building resilience is one way parents or caregivers can help their kids better navigate difficult times. Dr. Abby Rosenberg is a pediatric oncologist at Seattle Children's Hospital who studies resilience among young cancer patients, and she shared three findings on how we can build resilience in all children.
  • Your baby stopped breathing during sleep? It’s not your imagination 
    7.18.2018 – Smart Parenting 

    The pause in breath in babies is named Brief Resolved Unexplained Events (BRUE) by the AAP. Common in babies younger than a year, its symptoms include irregular or stopped breathing, skin turning pale or blue, change in muscle tone, and unresponsiveness. Dr. Joel Tieder, assistant professor of pediatrics at Seattle Children’s, said that while you cannot rule it out as a sign of an underlying medical condition, BRUE is rarely fatal. However, babies are considered high risk if they are younger than 60 days old, born premature, and had prior BRUE episodes.
  • Bonnie Ramsey Receives the Warren Alpert Foundation Prize
    Congratulations to Dr. Bonnie Ramsey, honored by the Warren Alpert Foundation for her transformative discoveries in pulmonology that led to the development of new life-altering treatments for those with cystic fibrosis. The Warren Alpert Foundation, in association with Harvard Medical School, honors trailblazing scientists whose work has improved the understanding, prevention, treatment or cure of human disease. Ramsey, along with the other four honorees, will be recognized at a symposium on Oct. 4 at Harvard Medical School. Read more.